Instrument Inactif

Communiqués CVTX

Actions

US1266671049

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

Communiqués

30/11/-1	CV THERAPEUTICS : to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008	PR
30/11/-1	CV THERAPEUTICS : Announces License Agreement for Ranexa(R) in Europe With Menarini Group	PR
30/11/-1	CV THERAPEUTICS : Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases	PR
30/11/-1	CV THERAPEUTICS : Reports Option Grants Under Nasdaq Marketplace Rule 4350	PR
30/11/-1	CV THERAPEUTICS : Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome	PR
30/11/-1	CV THERAPEUTICS : Receives European Approval for the Brand Name Ranexa(R)	PR
30/11/-1	CV THERAPEUTICS : Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award	PR
30/11/-1	CV THERAPEUTICS : CVT Announces That FDA Continues to Review Ranexa(R) Applications	PR
30/11/-1	CV THERAPEUTICS : to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008	PR
30/11/-1	CV THERAPEUTICS : Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina	PR
30/11/-1	CV THERAPEUTICS : Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)	PR
30/11/-1	CV THERAPEUTICS : Reports Option Grants Under Nasdaq Marketplace Rule 4350	PR
30/11/-1	Cv Therapeutics : European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina	PR
30/11/-1	Cv Therapeutics : CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008	PR
30/11/-1	Cv Therapeutics : CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results	PR
30/11/-1	Cv Therapeutics : CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350	PR
30/11/-1	Cv Therapeutics : CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology	PR
30/11/-1	Cv Therapeutics : CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008	PR
30/11/-1	Cv Therapeutics : CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008	PR
30/11/-1	CV THERAPEUTICS : Gilead Sciences donne son accord pour l'acquisition de CV Therapeutics au prix de 20,00 USD par action	BU
30/11/-1	CV THERAPEUTICS : CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer	PR
30/11/-1	CV THERAPEUTICS : Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer	PR
30/11/-1	CV THERAPEUTICS : CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal	PR
30/11/-1	CV THERAPEUTICS : Statement on Unsolicited Proposal From Astellas	PR
30/11/-1	CV THERAPEUTICS : FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c	PR